Treatment for Brain Metastases
Key Points
Key Points
In the United States, it is estimated that between 8% and 10% of patients with cancer will develop brain metastases representing ~200,000 new patients with brain metastases every year.
The most likely primary cancers to seed brain metastases are melanoma, lung adenocarcinoma, and those from lung, breast, melanoma, renal, kidney, esophagus, and, head and neck.
This guideline was developed by a multi-disciplinary team of medical oncologists, neurosurgeons, neuro-oncologists and radiation oncologists, and it integrates the latest evidence supporting the use of surgery, radiation, and medical therapies for patients with CNS metastases.
Treatment
...eatment...
...1.1Surgery may be offered for patients with br...
...ation 1.2Where surgery is considered, no recomm...
...ommendation 1.3No recommendation can be mad...
...n 2.1Patients with symptomatic brain metast...
...commendation 2.2For patients with...
...on 2.3 Osimertinib or icotinib may be...
...endation 2.4Alectinib, brigatinib, or...
...tion 2.5Pembrolizumab may be offered to patients...
....6Ipilimumab plus nivolumab (for al...
....7The combination of tucatinib, trastuzum...
...ndation 3.1Radiation therapy should not be off...
....2SRS alone (as opposed to WBRT or combination of...
...ion 3.3SRS alone should be offered t...
...dation 3.4SRS, WBRT, and the combination of SRS p...
...tion 3.5Memantine and hippocampal avoidance sho...
...commendation 3.6Radiation sensitizing agents shou...
...commendation 4.1For patients who will receive...
...that cancer clinical trials are vi...